Trial Profile
A Single Dose, Open Label, Randomized, Balanced, Crossover Study to Assess the Relative Bioavailability of ThreeFormulations and Food Effect on GSK1322322 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Aug 2023
Price :
$35
*
At a glance
- Drugs Lanopepden (Primary) ; Lanopepden (Primary)
- Indications Bacterial infections
- Focus Pharmacokinetics
- Sponsors GSK
- 30 Apr 2013 Results presented at the 23rd European Congress of Clinical Microbiology and Infectious Diseases.
- 31 Jul 2012 New trial record